Bone-Strengthening Therapy

These medicines slow the activity of cells that break down bone. They may be offered when cancer has spread to bone, when a plasma-cell disorder affects bone, or when cancer has caused high calcium. Treatment supports the wider cancer plan; it does not remove a tumour on its own. Dental health, kidney function, calcium levels and vitamin status may be checked before treatment.

The medicine may be given as an intravenous infusion or as an injection under the skin, depending on the drug and your clinical situation. The schedule is individualised. Your team reviews blood tests, symptoms and dental concerns, and may recommend calcium and vitamin D if suitable. Tell them about kidney disease, planned dental work and any previous jaw problems.

Short-lived flu-like symptoms, tiredness, muscle aches, nausea or injection-site discomfort can occur. Low calcium may cause tingling, cramps or muscle spasms. A rare but serious jaw problem called osteonecrosis has been associated with these medicines, especially around invasive dental treatment. Seek urgent advice for severe weakness, confusion, facial swelling, difficulty breathing or new severe pain.

Clinical use supports these medicines as part of care for selected people with cancer-related bone disease. They can lower the chance of some skeletal complications and may help with bone pain or high calcium, but the benefit varies with the cancer, bone involvement and chosen medicine. They are not a promise that fractures, pain or other complications will never occur.

Treatment is preventive and supportive. Keep dental care regular, report new pain promptly and do not start supplements without checking the dose and suitability with your team.

A specialist may discuss it for bone metastases, multiple myeloma, selected breast or prostate cancers with bone involvement, or cancer-related high calcium. The decision considers fracture risk, pain, blood results, kidney function, dental status and other cancer treatments.

The team confirms your medicines and recent blood results, checks the planned dose, and gives the infusion or injection. You can ask how to manage expected symptoms and when the next monitoring test is due. Keep a record of new pain, dental symptoms or tingling between visits.

Most people return to their usual routine according to how they feel and the route used. Drink fluids if your team advises this, use the agreed symptom-relief plan and attend blood-test appointments. Tell the service if symptoms are persistent or becoming more intense rather than waiting for the next dose.

Risks include low calcium, kidney effects, flu-like symptoms and dental or jaw complications. Rare atypical fractures and other medicine-specific effects may also be discussed. Never conceal new dental pain, loose teeth, numbness or a planned extraction.

Pain medicines, radiotherapy to a painful bone, surgery for an unstable fracture, physiotherapy and treatment of the underlying cancer may be combined with or used instead of bone-strengthening medicine. Persistent bone pain deserves assessment rather than self-treatment alone.

Seek an oncology team able to coordinate prescribing, laboratory monitoring, dental advice and pain or fracture care. Ask which medicine is planned, what symptoms require a call and who should manage dental treatment during therapy.